From a single serum sample, we quantify multiple biomarkers — known and newly discovered. Precision Diagnostics.
Using FDA-cleared technology, this is our core platform. It incorporates diagnostic testing algorithms into nuclear magnetic resonance (NMR) spectroscopy. It's the first modular software-based system for clinical diagnostics.
The FDA-cleared AXINON® LDL-p Test System, is a new tool physicians can use to measure lipoproteins for patients at risk for cardiovascular disease.
AXINON® lipoFIT® is a cardiovascular risk assessment, available as a CE-labeled in vitro diagnostic product in the EU.
AXINON® GFR(NMR) is a kidney function assay, available as a CE-labled in vitro diagnostic product in the EU.
Alex’ Story: Born with one kidney. What happens when it fails?
AXINON® HCC(NMR) is a liver cancer detection test, currently in development.
Cardiology
AXINON® LDL-p Test System: Now FDA-cleared, provides more detailed information about cardiac function than the standard LDL-C (low-density lipoprotein or “bad cholesterol”) measurement.
AXINON® lipoFIT®: For cardiovascular risk assessment.
Available as a CE-labled in vitro diagnostic product in the EU
Nephrology
AXINON® GFR(NMR): New kidney function assay that combines two novel biomarkers, valine and myo-inositol, with creatinine and cystatin C using highly accurate nuclear magnetic resonance (NMR) spectroscopy.
Available as a CE-labled in vitro diagnostic product in the EU
Hepatology
AXINON® HCC(NMR): Liver risk assessment and cancer early detection test.
In development
